Urinary biomarkers of phthalates exposure and risks of thyroid cancer and benign nodule


Phthalates have been reported to affect the function and growth of thyroid. However, there is little data on the effect of phthalates on thyroid oncogenesis. In the present study, the authors investigated the associations between phthalates exposure and the risks of thyroid cancer and benign nodule. We sex-matched 144 thyroid cancer, 138 benign nodule patients and 144 healthy adults from Wuhan, China. Eight phthalate metabolites in spot urine samples were quantified using high-performance liquid chromatography and tandem mass spectrometry. The associations of creatinine-corrected urinary phthalate metabolites with the risks of thyroid cancer and benign nodule were assessed using multivariable logistic regression models. It was found that urinary monomethyl phthalate (MMP), mono(2-ethyl-5hydroxyhexyl) phthalate (MEHHP) and mono(2-ethylhexyl) phthalate (MEHP) were associated with increased risks of thyroid cancer and nodule, with adjusted odds ratios (ORs) ranging from 1.74 to 4.78 comparing the extreme tertiles, and urinary monobutyl phthalate (MBP) was associated with decreased risks of thyroid cancer and benign nodule (all P for trends?

Authors: Liu C, Deng YL, Zheng TZ, Yang P, Jiang XQ, Liu EN, Miao XP, Wang LQ, Jiang M, Zeng Q.
; Full Source: Journal of Hazardous Materials. 2019 Sep 9; 383:121189. doi: 10.1016/j.jhazmat.2019.121189. [Epub ahead of print]